Induced pluripotent stem cells:origins, applications, and future perspectives  

作　　者：Jing ZHAO Wen-jie JIANG Chen SUN Cong-zhe HOU Xiao-mei YANG Jian-gang GAO 

机构地区：[1]School of Life Sciences, Shandong University

出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2013年第12期1059-1069,共11页浙江大学学报（英文版）B辑（生物医学与生物技术）

基　　金：supported by the National Natural Science Foundation of China(Nos.30871436,30973297,31171194,and 31271534);the National Basic Research Program(973)of China(Nos.2010CB945002 and 2014CB541703);the Shandong Provincial Science and Technology Key Program(No.2009GG10003039);the Independent Development Foundation of Shandong University(Nos.2012JC019 and 2012ZD030),China

摘　　要：Embryonic stem(ES)cells are widely used for different purposes,including gene targeting,cell therapy,tissue repair,organ regeneration,and so on.However,studies and applications of ES cells are hindered by ethical issues regarding cell sources.To circumvent ethical disputes,great efforts have been taken to generate ES cell-like cells,which are not derived from the inner cell mass of blastocyst-stage embryos.In 2006,Yamanaka et al.first reprogrammed mouse embryonic fibroblasts into ES cell-like cells called induced pluripotent stem(iPS)cells.About one year later,Yamanaka et al.and Thomson et al.independently reprogrammed human somatic cells into iPS cells.Since the first generation of iPS cells,they have now been derived from quite a few different kinds of cell types.In particular,the use of peripheral blood facilitates research on iPS cells because of safety,easy availability,and plenty of cell sources.Now iPS cells have been used for cell therapy,disease modeling,and drug discovery.In this review,we describe the generations,applications,potential issues,and future perspectives of iPS cells.Embryonic stem （ES） cells are widely used for different purposes, including gene targeting, celltherapy, tissue repair, organ regeneration, and so on. However, studies and applications of ES cells are hindered by ethical issues regarding cellsources. To circumvent ethical disputes, great efforts have been taken to generate ES cel-like cells, which are not derived from the inner cellmass of blastocyst-stage embryos. In 2006, Yamanaka et al. first re-programmed mouse embryonic fibroblasts into ES cell-like cells cal ed induced pluripotent stem （iPS） cells. About one year later, Yamanaka et al. and Thomson et al. independently reprogrammed human somatic cells into iPS cells. Since the first generation of iPS cells, they have now been derived from quite a few different kinds of celltypes. In particular, the use of peripheral blood facilitates research on iPS cells because of safety, easy availability, and plenty of cellsources. Now iPS cells have been used for celltherapy, disease modeling, and drug discovery. In this review, we describe the generations, applications, potential issues, and future perspectives of iPS cells.

关 键 词：Induced pluripotent stem cells ORIGIN Peripheral blood cells APPLICATION Potential issues 

分 类 号：R329[医药卫生—人体解剖和组织胚胎学]